# Eli Lilly and Company clinical trials: 2,115 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 2,115 trials with Eli Lilly and Company as lead sponsor, 150 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Eli Lilly and Company: 2,115 rows for $101.15, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 10 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 2,115
- Recruiting or not yet: 150
- Read on: November 19, 2026

## Trials

The 25 newest of 2,115, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07945314 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants | Eli Lilly and Company | Phase 1 | Not yet recruiting | Healthy Participants | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945314) |
| November 17, 2026 | NCT07943091 | A Study of LY3945262 in Healthy Participants | Eli Lilly and Company | Phase 1 | Not yet recruiting | Healthy Volunteers | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943091) |
| November 13, 2026 | NCT07935317 | A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer | Eli Lilly and Company | Phase 2 | Not yet recruiting | Breast Neoplasms | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935317) |
| November 13, 2026 | NCT07935304 | A Study Assessing Eloralintide (LY3841136) in Healthy Participants | Eli Lilly and Company | Phase 1 | Not yet recruiting | Healthy | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935304) |
| November 10, 2026 | NCT07928258 | A Study of LY4336619 in Adult Participants With Advanced Solid Tumors | Eli Lilly and Company | Phase 1 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Neoplasms, Germ Cell and Embryonal, Carcinoma, Non-Small-Cell Lung, Stomach... | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928258) |
| November 10, 2026 | NCT07928245 | A Study of Brenipatide in Participants With Major Depressive Disorder | Eli Lilly and Company | Phase 2 | Not yet recruiting | Major Depressive Disorder | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928245) |
| November 10, 2026 | NCT07928219 | A Study of LY3981314 in Participants With Autoimmune Hepatitis | Eli Lilly and Company | Phase 1 | Not yet recruiting | Hepatitis Autoimmune Disease, Hepatitis | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928219) |
| November 6, 2026 | NCT07920887 | A Study of Bimagrumab in Participants With HFpEF | Eli Lilly and Company | Phase 2 | Not yet recruiting | Heart Failure, Diastolic, Diastolic Heart Failure, Heart Failure, Normal Ejection Fraction, Heart Failure, Preserved... | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920887) |
| November 5, 2026 | NCT07918859 | A Study of Imlunestrant (LY3484356) in Healthy Female Participants | Eli Lilly and Company | Phase 1 | Not yet recruiting | Healthy | 343 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918859) |
| November 4, 2026 | NCT07915245 | A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy | Eli Lilly and Company | Phase 1 | Recruiting | Obesity, Overweight | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915245) |
| November 4, 2026 | NCT07914738 | A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a) | Eli Lilly and Company | Phase 1 | Recruiting | Lipoprotein(a) | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914738) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 22, 2026 | NCT07890376 | A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes | Eli Lilly and Company | Phase 2 | Not yet recruiting | Obesity, Overweight | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890376) |
| October 20, 2026 | NCT07883590 | A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS). | Eli Lilly and Company | Phase 1 | Not yet recruiting | Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883590) |
| October 20, 2026 | NCT07881887 | A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes | Eli Lilly and Company | Phase 1 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 617 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881887) |
| October 19, 2026 | NCT07881458 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881458) |
| October 19, 2026 | NCT07881432 | A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity | 2,115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881432) |
| October 9, 2026 | NCT07867340 | A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants... | Eli Lilly and Company | Phase 1 | Recruiting | C-Reactive Protein | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867340) |
| October 9, 2026 | NCT07867327 | A Study of LY4515100 in Healthy Male Participants | Eli Lilly and Company | Phase 1 | Recruiting | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867327) |
| September 28, 2026 | NCT07843459 | A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD) | Eli Lilly and Company | Phase 1 | Recruiting | Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid, Plasma | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843459) |
| September 24, 2026 | NCT07839936 | A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease | Eli Lilly and Company | Phase 2 | Recruiting | Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07839936) |
| September 24, 2026 | NCT07838155 | A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease | Eli Lilly and Company | Phase 4 | Not yet recruiting | Alzheimer Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838155) |
| September 18, 2026 | NCT07827612 | A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer | Eli Lilly and Company | Phase 2 | Not yet recruiting | Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3 | 161 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827612) |
| September 16, 2026 | NCT07822880 | A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India | Eli Lilly and Company | Phase 4 | Not yet recruiting | Thyroid Neoplasms, Carcinoma, Non-Small-Cell Lung | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822880) |
| September 14, 2026 | NCT07818967 | A Study of Abemaciclib (LY2835219) in Healthy Participants | Eli Lilly and Company | Phase 1 | Recruiting | Healthy Volunteers | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818967) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 801 |
| Phase 1/2 | 52 |
| Phase 2 | 471 |
| Phase 2/3 | 18 |
| Phase 3 | 536 |
| Phase 4 | 174 |
| Not applicable | 26 |
| Observational | 36 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 1,703 |
| Terminated | 132 |
| Recruiting | 130 |
| Active not recruiting | 87 |
| Withdrawn | 23 |
| Not yet recruiting | 20 |
| Approved for marketing | 9 |
| Enrolling by invitation | 5 |
| Available | 3 |
| No longer available | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 236 |
| Carcinoma, Non-Small-Cell Lung | 142 |
| Obesity | 117 |
| Overweight | 93 |
| Breast Neoplasms | 87 |
| Neoplasm Metastasis | 72 |
| Neoplasms | 72 |
| Diabetes Mellitus, Type 1 | 72 |
| Depressive Disorder, Major | 58 |
| Alzheimer Disease | 57 |
| Attention Deficit Disorder with Hyperactivity | 53 |
| Diabetes Mellitus | 48 |
| Colorectal Neoplasms | 36 |
| Arthritis, Rheumatoid | 35 |
| Schizophrenia | 33 |
| Migraine Disorders | 30 |
| Dermatitis, Atopic | 29 |
| Ovarian Neoplasms | 29 |
| Erectile Dysfunction | 28 |
| Pancreatic Neoplasms | 25 |
| Osteoporosis, Postmenopausal | 25 |
| Lung Neoplasms | 24 |
| Psoriasis | 23 |
| Osteoporosis | 23 |
| Eczema | 22 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Chicken restaurants in the United States](https://specstream.ai/data/businesses/chicken-restaurants/united-states)
- [Scientific laboratories in the United States](https://specstream.ai/data/businesses/scientific-laboratories/united-states)
- [Glass manufacturers in the United States](https://specstream.ai/data/businesses/glass-manufacturers/united-states)
- [Armenian restaurants in the United States](https://specstream.ai/data/businesses/armenian-restaurants/united-states)
- [Oral and maxillofacial surgery practices in the United States](https://specstream.ai/data/businesses/oral-and-maxillofacial-surgery-practices/united-states)
- [Dental laboratories in the United States](https://specstream.ai/data/businesses/dental-laboratories/united-states)
